Literature DB >> 27041545

Emotional manifestations of PD: Neurobiological basis.

Anna Castrioto1,2,3, Stéphane Thobois4,5, Sebastien Carnicella1,2, Audrey Maillet4, Paul Krack1,2,3.   

Abstract

Neuropsychiatric symptoms are common and disabling in PD. Their neurobiological bases are complex, partly because of the disease itself and partly because of the dopaminergic treatment. The aim of this review is to focus on the emotional manifestations stemming from the neurodegenerative process itself. We focus on depression, anxiety, apathy, and fatigue, which can all be part of the clinical spectrum of premotor disease and may be improved or masked by medications targeting parkinsonian motor signs or psychiatric symptoms as the disease progresses. Findings from clinical, neuroimaging, and animal studies are reviewed, showing a major contribution of the dopaminergic system to the pathophysiology of these disabling symptoms. Degeneration of noradrenergic and serotonergic projection systems also has an impact on psychiatric symptoms of PD. The available literature is reviewed, but at present there is a lack of studies that would allow disentangling the separate contribution of each of the monoaminergic systems. The use of a pragmatic classification of all these symptoms under the umbrella of hypodopaminergic behavioral syndrome seems clinically useful, as it emphasizes the crucial, although not exclusive, nature of their dopaminergic neurobiological basis, which has important implications in the clinical management of PD.
© 2016 International Parkinson and Movement Disorder Society. © 2016 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Parkinson's disease; anxiety; apathy; depression; dopamine

Mesh:

Year:  2016        PMID: 27041545     DOI: 10.1002/mds.26587

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  28 in total

Review 1.  Imaging the Etiology of Apathy, Anxiety, and Depression in Parkinson's Disease: Implication for Treatment.

Authors:  Stephane Thobois; Stephane Prange; Véronique Sgambato-Faure; Léon Tremblay; Emmanuel Broussolle
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08-18       Impact factor: 5.081

Review 2.  Cognitive and behavioral disorders in Parkinson's disease: an update. II: behavioral disorders.

Authors:  Luigi Trojano; Costanza Papagno
Journal:  Neurol Sci       Date:  2017-10-16       Impact factor: 3.307

3.  Attention in Parkinson's disease with fatigue: evidence from the attention network test.

Authors:  Caterina Pauletti; Daniela Mannarelli; Nicoletta Locuratolo; Luca Pollini; Antonio Currà; Lucio Marinelli; Steno Rinalduzzi; Francesco Fattapposta
Journal:  J Neural Transm (Vienna)       Date:  2016-10-25       Impact factor: 3.575

4.  Neurofunctional characteristics of executive control in older people with HIV infection: a comparison with Parkinson's disease.

Authors:  Eva M Müller-Oehring; Jui-Yang Hong; Kathleen L Poston; Helen M Brontë-Stewart; Edith V Sullivan; Lawrence McGlynn; Tilman Schulte
Journal:  Brain Imaging Behav       Date:  2022-03-16       Impact factor: 3.224

5.  Different effects of levodopa and subthalamic stimulation on emotional conflict in Parkinson's disease.

Authors:  Raul Martínez-Fernández; Astrid Kibleur; Stéphan Chabardès; Valérie Fraix; Anna Castrioto; Eugénie Lhommée; Elena Moro; Lucas Lescoules; Pierre Pelissier; Olivier David; Paul Krack
Journal:  Hum Brain Mapp       Date:  2018-09-26       Impact factor: 5.038

Review 6.  Insights into the Pathophysiology of Psychiatric Symptoms in Central Nervous System Disorders: Implications for Early and Differential Diagnosis.

Authors:  Giulia Menculini; Elena Chipi; Federico Paolini Paoletti; Lorenzo Gaetani; Pasquale Nigro; Simone Simoni; Andrea Mancini; Nicola Tambasco; Massimiliano Di Filippo; Alfonso Tortorella; Lucilla Parnetti
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

7.  Trait Impulsivity and Anhedonia: Two Gateways for the Development of Impulse Control Disorders in Parkinson's Disease?

Authors:  Jean-Luc Houeto; Robin Magnard; Jeffrey W Dalley; David Belin; Sebastien Carnicella
Journal:  Front Psychiatry       Date:  2016-05-30       Impact factor: 4.157

8.  Restoring Spinal Noradrenergic Inhibitory Tone Attenuates Pain Hypersensitivity in a Rat Model of Parkinson's Disease.

Authors:  Lei-Fang Cao; Xiao-Yan Peng; Ya Huang; Bing Wang; Feng-Ming Zhou; Ruo-Xiao Cheng; Li-Hua Chen; Wei-Feng Luo; Tong Liu
Journal:  Neural Plast       Date:  2016-09-26       Impact factor: 3.599

9.  Impact of Combined Subthalamic Nucleus and Substantia Nigra Stimulation on Neuropsychiatric Symptoms in Parkinson's Disease Patients.

Authors:  U Hidding; A Gulberti; A Horn; C Buhmann; W Hamel; J A Koeppen; M Westphal; A K Engel; C Gerloff; D Weiss; C K E Moll; M Pötter-Nerger
Journal:  Parkinsons Dis       Date:  2017-01-26

Review 10.  Non-pharmacologic interventions to treat apathy in Parkinson's disease: A realist review.

Authors:  Bria Mele; Zahinoor Ismail; Zahra Goodarzi; Tamara Pringsheim; Grace Lew; Jayna Holroyd-Leduc
Journal:  Clin Park Relat Disord       Date:  2021-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.